Clinical trial
An Open-label Multi-center, Randomized Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
NCT00116753 is registered in ClinicalTrials.gov with Ferring Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Multi-center, Randomized Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
- Lead sponsor
- Ferring Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2005
- Completion date
- November 30, 2006
- Enrollment
- 460 (actual)
- Sites
- 56
Conditions
As the registry lists them; a condition with its own page is linked.
prostate cancer